TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05934331: An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of the LM-302 Combination With Other Anti-tumor Treatment in Subjects With CLDN18.2-positive Advanced Gastro-Intestina

Sponsor: LaNova Medicines Zhejiang Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 632 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05934331 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05934331 Rescue Dossier →